作者
Pierre Sesques, Emmanuelle Ferrant, Violaine Safar, Florent Wallet, Jérémie Tordo, Anthony Dhomps, Lionel Karlin, Gabriel Brisou, Marlène Vercasson, Carole Hospital‐Gustem, Vérane Schwiertz, Florence Ranchon, Catherine Rioufol, Marion Choquet, Pierre Sujobert, Dana Ghergus, Fadhela Bouafia, Camille Golfier, Helène Lequeu, Anne Lazareth, Silvana Novelli, Perrine Devic, Alexandra Traverse Glehen, Sébastien Viel, Fabienne Venet, Valérie Mialou, Olivier Hequet, Adrien Chauchet, Yazid Arkam, Emmanuelle Nicolas‐Virelizier, Frederic Peyrade, Doriane Cavalieri, Florence Ader, Hervé Ghesquières, Gilles Salles, Emmanuel Bachy
发表日期
2020/11
期刊
American journal of hematology
卷号
95
期号
11
页码范围
1324-1333
出版商
John Wiley & Sons, Inc.
简介
Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi‐cel and tisa‐cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty‐one patients were infused. The median age at infusion was 59 years old (range 27‐75 years). The median number of prior therapies was 3 (range, 2‐6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow‐up after infusion of 5.7 months, the median progression …
学术搜索中的文章
P Sesques, E Ferrant, V Safar, F Wallet, J Tordo… - American journal of hematology, 2020